Erasca Surges After Cancer Drug Shows 62% Response Rate

(P1) Erasca Inc. shares surged after the company released positive early data for its experimental cancer therapy, ERAS-0015, showing a 62 percent response rate in certain lung cancer patients and setting a new benchmark in the difficult-to-treat category of RAS-mutant tumors. The results position the drug as a potentially best-in-class treatment and a serious competitor in a field targeted by multiple biotech firms.

(P2) “I’m excited about both datasets, but I think lung is more definitive at this point,” Erasca CEO Jonathan Lim told STAT. “The pancreatic results are maturing, but are very, very promising.”

(P3) The preliminary Phase 1 data showed an unconfirmed objective response rate of 62 percent in patients with advanced non-small cell lung cancer (NSCLC) who had previously received other treatments. In a subset of lung cancer patients who had failed both immunotherapy and platinum-based chemotherapy, the response rate was 75 percent. The drug also shrank tumors in 40 percent of patients with advanced pancreatic cancer, according to the company's announcement.

(P4) The data provides an early proof-of-concept for Erasca’s pan-RAS “molecular glue” approach, a technology designed to inhibit all major versions of the cancer-driving RAS protein family. With a market cap that has climbed to $6.68 billion on the back of a 1,446 percent stock surge over the past year, investors are betting these results could disrupt the multi-billion dollar market for KRAS-targeted therapies.

A New Approach to a Notorious Target

For decades, the RAS family of proteins was considered “undruggable.” When mutated, these proteins get stuck in an “on” state, driving uncontrolled cell growth in many of the most lethal cancers, including lung, pancreatic, and colorectal. Erasca’s ERAS-0015 is a small molecule designed to act as a “molecular glue,” forcing the cell’s own waste-disposal machinery to tag and destroy these faulty RAS proteins.

Unlike mutant-selective inhibitors that target only one specific RAS mutation, ERAS-0015 is a pan-RAS inhibitor, designed to work against multiple RAS variants. This could give it a broader application and potentially prevent the development of treatment resistance. The company reported the drug has favorable safety and pharmacokinetic properties, with responses seen at doses as low as eight milligrams daily.

Wall Street Raises Price Targets

The positive results prompted a flurry of analyst upgrades. Stifel raised its price target on Erasca to $30 from $20, maintaining a Buy rating. Analyst Laura Prendergast issued the update after meeting with company management, noting the firm’s confidence in the lung cancer opportunity and its strategy for pancreatic cancer, where it plans a first-line combination with chemotherapy.

Other firms followed suit, with H.C. Wainwright raising its target to $20 and Jefferies reiterating a $21 target. Analysts see the drug’s tolerability profile as a key differentiator, particularly for combination therapies. The results also compare favorably to data from Revolution Medicines’ competing drug, daraxonrasib, which recently showed it could double survival in pancreatic cancer patients.

Erasca confirmed it has enough cash to fund operations into the second half of 2028, giving it a substantial runway to advance ERAS-0015 through further clinical trials. The company plans to pursue a combination with cetuximab in colorectal cancer, further expanding the drug’s potential footprint.

This article is for informational purposes only and does not constitute investment advice.